ClinicalTrials.gg
RecruitingNCT06809764RERUNUpdated Aug 18, 2026

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

An observational study in Non-small Cell Lung Cancer, sponsored by Daiichi Sankyo. Recruiting at 36 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Daiichi Sankyo · Observational

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo — 5 open to participants now, 16 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Daiichi Sankyo.

Started
2025
with 1 other
Observational
6 of 41
1 open now
Primary completion
2027-02
later than 7 of 15 live
Registered
38th of 41
by date

Among the 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo, this one is one of 2 that started in 2025, is one of 6 observational ones, reaches primary completion later than 7 of the 15 other live ones, and was the 38th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo, or all of them as a file.
02

Study summary

Trastuzumab deruxtecan (T-DXd) is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of T-DXd used in Chinese lung cancer patients with HER2 mutations.

This real world, prospective study will assess the effectiveness and safety of T-DXd in patients with locally advanced or metastatic, HER2 mutation-positive NSCLC in real-world setting.

Read the detailed description

T-DXd is an approved therapy in China for locally advanced or metastatic NSCLC patients with human epidermal growth factor receptor 2 mutations (HER2m). In previous clinical trials, T-DXd demonstrated efficacy and manageable safety profiles in the ≥ second-line setting for NSCLC harboring HER2m. However, patient populations are more diverse in routine practice and no real-world data of T-DXd used in Chinese lung cancer patients with HER2 mutations exist.

This study will assess the effectiveness of ≥ second-line treatment of T-DXd in real-world setting as the primary objective. Secondary objectives will further assess the effectiveness and overall survival of ≥ second-line treatment of T-DXd in real-world setting as well as evaluate the safety and tolerability of any-line treatment of T-DXd in real-world setting. This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on T-DXd will be enrolled in this study.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Locally advanced or metastatic NSCLC
  • HER2 mutations
  • T-DXd
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

NSCLC patients with HER2 mutations who receive T-DXd based on physicians' discretion will be enrolled from about 30 sites in China.

Eligibility criteria

The key inclusion criteria for this study are:

  1. Age ≥18 years at signing form (ICF).
  2. documented unresectable and/or non-squamous NSCLC.
  3. Documented any known activating mutation.
  4. (ECOG) performance status (PS) 0-2.
  5. Patients who receive T-DXd based on physicians' discretion (Newly received or just have started the first dose no longer than 2 months before enrollment).

The key exclusion criteria for this study are:

  1. Previously treated with HER2-targeted/directed therapies, including:

    • tyrosine kinase inhibitors [TKIs] targeting HER2 mutations, except for pan-HER class TKIs.
    • an ADC, containing a chemotherapeutic agent targeting topoisomerase I
  2. Has spinal cord compression or clinically active , defined as untreated and symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms.
  3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension active bleeding diatheses, etc.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • NSCLC patients with HER2 mutations

    Patients with NSCLC with HER2 mutations who receive T-DXd based on physician's decisions will be enrolled.

    Other: No drug

Interventions

  • OtherNo drug

    This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on T-DXd will be enrolled in this study.

This study also gives Trastuzumab deruxtecan. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) by Investigator Assessment in Real-world Setting (rwPFS)

    rwPFS is defined as the time from the initiated date of ≥ second-line treatment of T-DXd until disease progression or death by investigator report as recorded in the electronic case report forms (eCRF).

    Time frame: Baseline up to approximatley 2 years

Secondary outcomes

  1. Time to Treatment Discontinuation or Death (TTD)

    TTD is defined as the time from the initiated date of ≥ second-line treatment of T-DXd to the date of treatment discontinuation or death from any cause.

    Time frame: Baseline up to approximately 2 years

  2. Best Overall Response Rate (BORR)

    BORR is defined as the percentage of patients with complete response (CR) or partial response (PR) as assessed by investigator for ≥ second-line treatment of T-DXd. Based on RECIST guidelines, CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

    Time frame: Baseline up to approximately 2 years

  3. Overall Survival

    Overall survival is defined as the time from the initiated date of ≥ second-line treatment of T-DXd until death due to any cause.

    Time frame: Baseline up to approximately 2 years

  4. Number of Patients Reporting Treatment-related Adverse Events (TRAEs), Adverse Events of Special Interests (AESIs), and AEs Leading to Dose Interruption, Reduction, Discontinuation

    TRAEs, AESIs and AEs leading to dose interruption, reduction, discontinuation will be graded by the investigators using National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) version 5.0 and coded using the medical dictionary for regulatory activities (MedDRA).

    Time frame: Baseline up to approximately 2 years

07

Study locations

29 of 36 sites recruiting
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, 100021, China
    Not yet recruiting
    • Principal Investigator · Contact
  • The History of Beijing Tiantan Hospital, Capital Medical University
    Beijing, 100070, China
    Recruiting
    • Principal Investigator · Contact
  • Peking University International Hospital
    Beijing, 100125, China
    Recruiting
    • Principal Investigator · Contact
  • Beijing Cancer Hospital
    Beijing, 100142, China
    Recruiting
    • Principal Investigator · Contact
  • Peking University Third Hospital
    Beijing, 100191, China
    Recruiting
    • Principal Investigator · Contact
  • Beijing Chest Hospital, Capital Medical University
    Beijing, 101149, China
    Recruiting
    • Principal Investigator · Contact
  • Hunan Second People's Hospital
    Changsha, 410007, China
    Recruiting
    • Principal Investigator · Contact
  • Fujian Cancer Hospital
    Fuzhou, 350014, China
    Recruiting
    • Principal Investigator · Contact
  • Dongguan People's Hospital
    Guangdong, 523000, China
    Recruiting
    • Principal Investigator · Contact
  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University
    Guangzhou, 510060, China
    Recruiting
    • Principal Investigator · Contact
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, 510062, China
    Recruiting
    • Principal Investigator · Contact
  • Zhejiang Cancer Hospital
    Hangzhou, 310022, China
    Recruiting
    • Principal Investigator · Contact
  • Cancer Hospital Chinese Academy of Medical Sciences (Langfang Section)
    Hebei, 065000, China
    Recruiting
    • Principal Investigator · Contact
  • Anhui Provincial Cancer Hospital
    Hefei, 230031, China
    Recruiting
    • Principal Investigator · Contact
  • Hubei Cancer Hospital
    Hubei, 430079, China
    Recruiting
    • Principal Investigator · Contact
  • Nanjing Drum Tower Hospital
    Jiangsu, 210008, China
    Recruiting
    • Principal Investigator · Contact
  • Affiliated Hospital of Nantong University
    Jiangsu, 226001, China
    Recruiting
    • Principal Investigator · Contact
  • Jiangxi Cancer Hospital
    Jiangxi, 330029, China
    Recruiting
    • Principal Investigator · Contact
  • First Affiliated Hospital of Shandong First Medical University
    Jinan, 250014, China
    Recruiting
    • Principal Investigator · Contact
  • Cancer Hospital of Shandong First Medical University
    Jinan, 250103, China
    Not yet recruiting
    • Principal Investigator · Contact
  • The First Affiliated Hospital of Jinzhou Medical University
    Jinzhou, 121001, China
    Not yet recruiting
    • Principal Investigator · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, 330000, China
    Not yet recruiting
    • Principal Investigator · Contact
  • Guangxi Medical University Cancer Hospital
    Nanning, 541000, China
    Not yet recruiting
    • Principal Investigator · Contact
  • The Affiliated Hospital of Qingdao University
    Shandong, 266000, China
    Recruiting
    • Principal Investigator · Contact
  • Ruijin Hospital, Shanghai Jiaotong University School Of Medicine
    Shanghai, 200025, China
    Recruiting
    • Principal Investigator · Contact
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
    Not yet recruiting
    • Principal Investigator · Contact
  • Shanghai Pulmonary Hospital
    Shanghai, 200433, China
    Recruiting
    • Principal Investigator · Contact
  • Shanghai Geriatric Medical Hospital
    Shanghai, 201100, China
    Recruiting
    • Principal Investigator · Contact
  • The First Hospital of China Medical University
    Shenyang, 110001, China
    Recruiting
    • Principal Investigator · Contact
  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
    Shenzhen, 518116, China
    Recruiting
    • Principal Investigator · Contact
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, 050011, China
    Recruiting
    • Principal Investigator · Contact
  • Shangxi Provincial Cancer Hospital
    Taiyuan, 030013, China
    Recruiting
    • Principal Investigator · Contact
  • The First Affiliated Hospital of Xiamen University
    Xiamen, 361102, China
    Recruiting
    • Principal Investigator · Contact
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Zhejiang, 310009, China
    Recruiting
    • Principal Investigator · Contact
  • Henan Cancer Hospital
    Zhengzhou, 450052, China
    Recruiting
    • Principal Investigator · Contact
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, 450052, China
    Not yet recruiting
    • Principal Investigator · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 23 months after the start.

Of 142 industry-sponsored observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's planned 23 months is below that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2025
First posted
Feb 5, 2025
StartActual
Feb 21, 2025
Primary completionEst.
Feb 12, 2027
CompletionEst.
Feb 12, 2027
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06809764
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Feb 5, 2025
Start date
Feb 21, 2025
Primary completion
Feb 12, 2027 (estimated)
Completion
Feb 12, 2027 (estimated)
Last update
Aug 18, 2026

Study contacts

Contact for Clinical Trial Information
Contact
CTRinfo_us@daiichisankyo.com
908-992-6400
Project Manager
study director · Daiichi Sankyo Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion